Modulatory effects by CB1 receptors on rat spinal locomotor networks after sustained application of agonists or antagonists

Neuroscience

Volumn 303, Issue , 2015, Pages 16-33

  Veeraraghavan, P ^a   Nistri, A ^a  

^a SISSA   (Italy)

Author keywords

AM 251; Anandamide; CAMP; Cannabinoid receptor 1; Endocannabinoids; Fictive locomotion

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CYCLIC AMP; 4 AMINOBUTYRIC ACID; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AMPLITUDE MODULATION; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN FUNCTION; DORSAL ROOT; LOCOMOTION; MOLECULAR DYNAMICS; MOTOR PERFORMANCE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE FUNCTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SPINAL CORD; STIMULUS RESPONSE; SYNAPTIC TRANSMISSION; ACTION POTENTIAL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NERVE CELL; NERVE CELL INHIBITION; PHYSIOLOGY; REFLEX; WISTAR RAT;

ACTION POTENTIALS; ANIMALS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; GAMMA-AMINOBUTYRIC ACID; LOCOMOTION; NERVE NET; NEURAL INHIBITION; NEURONS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; REFLEX; SPINAL CORD; SYNAPTIC TRANSMISSION;

EID: 84936857998     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.06.045     Document Type: Article

References (75)

1. Barrière G., Mellen N., Cazalets J.R. Neuromodulation of the locomotor network by dopamine in the isolated spinal cord of newborn rat. Eur J Neurosci 2004, 19:1325-1335.
2. Beato M., Nistri A. Interaction between disinhibited bursting and fictive locomotor patterns in the rat isolated spinal cord. J Neurophysiol 1999, 82:2029-2038.
3. Berghuis P., Rajnicek A.M., Morozov Y.M., Ross R.A., Mulder J., Urbán G.M., Monory K., Marsicano G., Matteoli M., Canty A., Irving A.J., Katona I., Yanagawa Y., Rakic P., Lutz B., Mackie K., Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007, 316:1212-1216.
4. Bianchetti E., Mladinic M., Nistri A. Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitro. Cell Death Dis 2013, 4:e707-e718.
5. Bifulco M., Pisanti S. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat Rev Drug Discov 2009, 8:594.
6. Borgelt L.M., Franson K.L., Nussbaum A.M., Wang G.S. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013, 33:195-209.
7. Bosier B., Sarre S., Smolders I., Michotte Y., Hermans E., Lambert D.M. Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists. Neuropharmacology 2010, 59:503-510.
8. Bracci E., Ballerini L., Nistri A. Spontaneous rhythmic bursts induced by pharmacological block of inhibition in lumbar motoneurons of the neonatal rat spinal cord. J Neurophysiol 1996, 75:640-647.
9. Burston J.J., Sagar D.R., Shao P., Bai M., King E., Brailsford L., Turner J.M., Hathway G.J., Bennett A.J., Walsh D.A., Kendall D.A., Lichtman A., Chapman V. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 2013, 8:e80440.
10. Castillo P.E., Younts T.J., Chávez A.E., Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 2012, 76:70-81.
11. Cazalets J.R., Sqalli-Houssaini Y., Clarac F. Activation of the central pattern generators for locomotion by serotonin and excitatory amino acids in neonatal rat. J Physiol 1992, 455:187-204.
12. Chaouloff F., Dubreucq S., Bellocchio L., Marsicano G. Endocannabinoids and motor behavior: CB1 receptors also control running activity. Physiology (Bethesda) 2011, 26:76-77.
13. Childers S.R., Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 1996, 52:819-827.
14. Cifra A., Mazzone G.L., Nani F., Nistri A., Mladinic M. Postnatal developmental profile of neurons and glia in motor nuclei of the brainstem and spinal cord, and its comparison with organotypic slice cultures. Dev Neurobiol 2012, 72:1140-1160.
15. D'Amico J.M., Condliffe E.G., Martins K.J., Bennett D.J., Gorassini M.A. Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity. Front Integr Neurosci 2014, 8:1-24.
16. Després J.P., Golay A., Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
17. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000, 75:2434-2444.
18. Dietz V. Behavior of spinal neurons deprived of supraspinal input. Nat Rev Neurol 2010, 6:167-174.
19. El Manira A., Kyriakatos A. The role of endocannabinoid signaling in motor control. Physiology (Bethesda) 2010, 25:230-238.
20. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
21. Etlin A., Blivis D., Ben-Zwi M., Lev-Tov A. Long and short multifunicular projections of sacral neurons are activated by sensory input to produce locomotor activity in the absence of supraspinal control. J Neurosci 2010, 30:10324-10336.
22. Farquhar-Smith W.P., Egertová M., Bradbury E.J., McMahon S.B., Rice A.S., Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000, 15:510-521.
23. Fulton B.P., Walton K. Electrophysiological properties of neonatal rat motoneurones studied in vitro. J Physiol 1986, 370:651-678.
24. Galve-Roperh I., Chiurchiù V., Díaz-Alonso J., Bari M., Guzmán M., Maccarrone M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res 2013, 52:633-650.
25. Ginovart N., Tournier B.B., Moulin-Sallanon M., Steimer T., Ibanez V., Millet P. Chronic δ9-tetrahydrocannabinol exposure induces a sensitization of dopamine D2/3 receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology 2012, 37:2355-2367.
26. Gonzalez-Islas C., Garcia-Bereguiain M.A., Wenner P. Tonic and transient endocannabinoid regulation of AMPAergic miniature postsynaptic currents and homeostatic plasticity in embryonic motor networks. J Neurosci 2012, 32:13597-13607.
27. Grillner S. The motor infrastructure: from ion channels to neuronal networks. Nat Rev Neurosci 2003, 4:573-586.
28. Grillner S. Biological pattern generation: the cellular and computational logic of networks in motion. Neuron 2006, 52:751-766.
29. Grillner S., Ekeberg O., El Manira A., Lansner A., Parker D., Tegnér J., Wallén P. Intrinsic function of a neuronal network - a vertebrate central pattern generator. Brain Res Rev 1998, 26:184-197.
30. Heidemann M., Streit J., Tscherter A. Functional regeneration of intraspinal connections in a new in vitro model. Neuroscience 2014, 262:40-52.
31. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
32. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30years of progress. Neuropharmacology 2004, 47:345-358.
33. Hudson B.D., Hébert T.E., Kelly M.E. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010, 77:1-9.
34. Iannotti F.A., Silvestri C., Mazzarella E., Martella A., Calvigioni D., Piscitelli F., Ambrosino P., Petrosino S., Czifra G., Bíró T., Harkany T., Taglialatela M., Di Marzo V. The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels. Proc Natl Acad Sci U S A 2014, 111:E2472-E2481.
35. Järbe T.U., Ross T., DiPatrizio N.V., Pandarinathan L., Makriyannis A. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 2006, 85:243-252.
36. Jennings E.A., Vaughan C.W., Christie M.J. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol 2001, 534:805-812.
37. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat Rev Drug Discov 2008, 7:961-963.
38. Kato A., Punnakkal P., Pernía-Andrade A.J., von Schoultz C., Sharopov S., Nyilas R., Katona I., Zeilhofer H.U. Endocannabinoid-dependent plasticity at spinal nociceptor synapses. J Physiol 2012, 590:4717-4733.
39. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012, 35:529-558.
40. Kettunen P., Kyriakatos A., Hallén K., El Manira A. Neuromodulation via conditional release of endocannabinoids in the spinal locomotor network. Neuron 2005, 45:95-104.
41. Kiehn O. Locomotor circuits in the mammalian spinal cord. Annu Rev Neurosci 2006, 29:279-306.
42. Kiehn O. Development and functional organization of spinal locomotor circuits. Curr Opin Neurobiol 2011, 21:100-109.
43. Kiehn O., Kjaerulff O. Distribution of central pattern generators for rhythmic motor outputs in the spinal cord of limbed vertebrates. Ann N Y Acad Sci 1998, 860:110-129.
44. Kim J., Alger B.E. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci 2010, 13(5):592-600.
45. Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G., Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014, 82:1556-1563.
46. Kremer E., Lev-Tov A. Localization of the spinal network associated with generation of hindlimb locomotion in the neonatal rat and organization of its transverse coupling system. J Neurophysiol 1997, 77:1155-1170.
47. Kudo N., Nishimaru H. Reorganization of locomotor activity during development in the prenatal rat. Ann N Y Acad Sci 1998, 860:306-317.
48. Lee J., Di Marzo V., Brotchie J.M. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and l-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 2006, 51:557-565.
49. Levy R.A. The role of GABA in primary afferent depolarization. Prog Neurobiol 1977, 9:211-267.
50. Li L., Bender K.J., Drew P.J., Jadhav S.P., Sylwestrak E., Feldman D.E. Endocannabinoid signaling is required for development and critical period plasticity of the whisker map in somatosensory cortex. Neuron 2009, 64:537-549.
51. Liu C.H., Heynen A.J., Shuler M.G.H., Bear M.F. Cannabinoid receptor blockade reveals parallel plasticity mechanisms in different layers of mouse visual cortex. Neuron 2008, 58:340-345.
52. Long S.K., Evans R.H., Cull L., Krijzer F., Bevan P. An in vitro mature spinal cord preparation from the rat. Neuropharmacology 1988, 27:541-546.
53. Mandadi S., Nakanishi S.T., Takashima Y., Dhaka A., Patapoutian A., McKemy D.D., Whelan P.J. Locomotor networks are targets of modulation by sensory transient receptor potential vanilloid 1 and transient receptor potential melastatin 8 channels. Neuroscience 2009, 162:1377-1397.
54. Manzanares J., Julian M.D., Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006, 4:239-257.
55. Marchetti C., Beato M., Nistri A. Alternating rhythmic activity induced by dorsal root stimulation in the neonatal rat spinal cord in vitro. J Physiol 2001, 530:105-112.
56. Martin B.R., Sim-Selley L.J., Selley D.E. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 2004, 25:325-330.
57. McCrea D.A., Rybak I.A. Organization of mammalian locomotor rhythm and pattern generation. Brain Res Rev 2008, 57:134-146.
58. McLaughlin P.J., Thakur G.A., Vemuri V.K., McClure E.D., Brown C.M., Winston K.M., Wood J.T., Makriyannis A., Salamone J.D. Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. Pharmacol Biochem Behav 2013, 109:16-22.
59. Nistri A., Constanti A. Pharmacological characterization of different types of GABA and glutamate receptors in vertebrates and invertebrates. Prog Neurobiol 1979, 13:117-235.
60. Ostroumov K., Grandolfo M., Nistri A. The effects induced by the sulphonylurea glibenclamide on the neonatal rat spinal cord indicate a novel mechanism to control neuronal excitability and inhibitory neurotransmission. Br J Pharmacol 2007, 150:47-57.
61. Pagotto U., Vicennati V., Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005, 37:270-275.
62. Pan B., Wang W., Long J.Z., Sun D., Hillard C.J., Cravatt B.F., Liu Q.S. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 2009, 331:591-597.
63. Parker D., Zhang W., Grillner S. Substance P modulates NMDA responses and causes long-term protein synthesis-dependent modulation of the lamprey locomotor network. J Neurosci 1998, 18:4800-4813.
64. Pernía-Andrade A.J., Kato A., Witschi R., Nyilas R., Katona I., Freund T.F., Watanabe M., Filitz J., Koppert W., Schüttler J., Ji G., Neugebauer V., Marsicano G., Lutz B., Vanegas H., Zeilhofer H.U. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009, 325:760-764.
65. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K., Mechoulam R., Ross R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010, 62:588-631.
66. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
67. Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 2014, 76:228-234.
68. Piomelli D., Hohmann A.G., Seybold V., Hammock B.D. A lipid gate for the peripheral control of pain. J Neurosci 2014, 34:15184-15191.
69. Poncelet M., Maruani J., Calassi R., Soubrié P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003, 43:216-218.
70. Rudomin P. In search of lost presynaptic inhibition. Exp Brain Res 2009, 196:139-151.
71. Steffens M., Engler C., Zentner J., Feuerstein T.J. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br J Pharmacol 2004, 141:1193-1203.
72. Steffens M., Zentner J., Honegger J., Feuerstein T.J. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem Pharmacol 2005, 69:169-178.
73. Taccola G., Margaryan G., Mladinic M., Nistri A. Kainate and metabolic perturbation mimicking spinal injury differentially contribute to early damage of locomotor networks in the in vitro neonatal rat spinal cord. Neuroscience 2008, 155:538-555.
74. Watkins J.C., Evans R.H. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981, 21:165-204.
75. Whitlow C.T., Freedland C.S., Porrino L.J. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology 2002, 161:129-136.